Drug Safety? There (Should Be) an App for That, FDA Says

The GMP Letter
The FDA is seeking public comment on how it should regulate prescription drug software apps and says some software applications might have to be regulated as a device — such as a software program that uses advanced algorithms to scan skin lesions for evidence of cancer.

To View This Article:


Subscribe To The GMP Letter

Buy This Article Now

Add this article to your cart for $40.00